Key result
Cardiometabolic risk factor modification targets elevated atherogenesis and cardiovascular disease in people with HIV.
Answers are grounded in this paper and cite their sources.
This review summarizes the epidemiology, pathogenesis, and management of cardiometabolic risk factors in people living with HIV to prevent cardiovascular events.
Effective antiretroviral therapy (ART) is now nearly ubiquitous. However, the survival benefits conferred with ART contribute to an aging human immunodeficiency virus (HIV) population and increased risk of chronic diseases, like atherosclerotic cardiovascular disease (ASCVD). Furthermore, HIV is a known risk enhancer of ASCVD and acknowledged as such in the current 2018 AHA/ACC Blood Cholesterol guidelines [1]. This makes cardiovascular risk factor identification and modification among people living with HIV (PLWH) of increasing importance to prevent cardiovascular events. In this review, we aim to summarize the epidemiology and pathogenesis of how HIV is linked to atherogenesis and to discuss cardiometabolic risk factor modification specific to PLWH, covering obesity, hypertension, insulin resistance, metabolic dysfunction-associated steatotic liver disease, and dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Kobe et al. (2024) conducted a review in Human immunodeficiency virus (HIV) and cardiometabolic risk. Cardiometabolic risk factor modification was evaluated. This review summarizes the epidemiology and pathogenesis linking HIV to atherogenesis and discusses cardiometabolic risk factor modification specific to people living with HIV.
Synapse has enriched 10 related papers. Consider them for comparative context: